[ij] [ij] [ij] 
Email id

Research Journal of Pharmacology and Pharmacodynamics
Year : 2016, Volume : 8, Issue : 2
First page : ( 65) Last page : ( 70)
Print ISSN : 0975-4407. Online ISSN : 2321-5836.
Article DOI : 10.5958/2321-5836.2016.00012.4

Evaluation of Anticancer Activity of Ethanolic and Ethylacetoacetate Extracts of Sweet Cherry Against Human Breast Cancer Cell Line MCF-7

Lavanya M.1, Bhaumik Asish1,*, Reddy A. Gopi2, Manasa Ch.1, Kalyani B.1, Sushmitha S.1

1Department of Pharmaceutical Chemistry, Teja College of Pharmacy, Kodad, Nalgonda-508206, Telangana State, India

2Department of Pharmaceutical Chemistry, SANA College of Pharmacy, Kodad, Nalgonda-508206, Telangana State, India

*Corresponding Author E-mail: bhaumik.asish@gmail.com

Online published on 21 July, 2016.


MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. The MCF7 line retains several characteristics of differentiated mammary epithelium including ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes. The cells express the WNT7B oncogene. Growth of MCF7 cells is inhibited by tumor necrosis factor alpha (TNF alpha). Secretion of IGFBP's can be modulated by treatment with anti-estrogens. PIK3CA helical mutations were identified in MCF-7, but with low AKT activation. The main objective of the present research work is to isolate the bioactive molecules and evaluate the in vitro anticancer activity of ethanolic and ethyl acetoacetate extracts of sweet cherry (EEC and EAAEC) of Prunus avium. The in vitro anticancer activity was carried out against human breast cancer cell line MCF-7 by MTT assay. The results obtained from the in-vitro studies performed by MTT assay by using human breast cancer cell line MCF-7 displayed that the various extracts of sweet cherry (EEC and EAAEC) possessed a very good anticancer activity. From the present studied it had been concluded that EEC and EAAEC, all were exhibiting the potential capability to inhibit the cancer cell when compared with standard drug doxorubicin and the cell growth inhibition of EEC and EAAEC was found to be the highest 92.90% growth inhibition at 10 μg (IC50 = 2.4 μg/ml) and EAAEC with the 92.49% growth inhibition at 10 μg (IC50 = 2.9 μg/ml).



MCF-7, WNT7B oncogene, TNF alpha, anticancer, MTT assay, IC50 etc.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
739,822,357 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.